Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Pulmonx raises $32 million for emphysema device marketing: Overseas marketing of Pulmonx' Chartis pulmonary assessment system and Zephyr endobronchial valve for emphysema patients will be supported by a $32 million private equity financing, announced Feb. 22. Headquartered in Redwood City, Calif., Pulmonx "now plans to invest significantly to grow direct and indirect sales, marketing, and clinical development activities throughout the EU," the company says. Both of the devices are CE marked. Chartis launched in Europe last December through a network of distribution partners in key countries. Zephyr was acquired through Pulmonx' purchase of Emphasys Medical in May 2009 (1"The Gray Sheet" May 18, 2009). The recent financing was co-led by venture capital firm HealthCap and Kleiner Perkins Caufield & Byers. "The company expects that this round of financing will fund the expansion of its commercial operations through to positive cash flow and profitability," Pulmonx notes
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel